149 related articles for article (PubMed ID: 15968104)
1. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
2. Myeloma cells (5TMM) and their interactions with the marrow microenvironment.
Menu E; Asosingh K; Van Riet I; Croucher P; Van Camp B; Vanderkerken K
Blood Cells Mol Dis; 2004; 33(2):111-9. PubMed ID: 15315788
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma biology: lessons from the 5TMM models.
Vanderkerken K; Asosingh K; Croucher P; Van Camp B
Immunol Rev; 2003 Aug; 194():196-206. PubMed ID: 12846816
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
7. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
8. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
9. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
10. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K
Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411
[TBL] [Abstract][Full Text] [Related]
12. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
[TBL] [Abstract][Full Text] [Related]
13. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
Vanderkerken K; De Greef C; Asosingh K; Arteta B; De Veerman M; Vande Broek I; Van Riet I; Kobayashi M; Smedsrod B; Van Camp B
Br J Cancer; 2000 Feb; 82(4):953-9. PubMed ID: 10732771
[TBL] [Abstract][Full Text] [Related]
14. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
[TBL] [Abstract][Full Text] [Related]
15. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
[TBL] [Abstract][Full Text] [Related]
16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
17. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
18. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.
Hu Y; Wang YD; Guo T; Wei WN; Sun CY; Zhang L; Huang J
Cancer Genet Cytogenet; 2007 Oct; 178(1):1-10. PubMed ID: 17889702
[TBL] [Abstract][Full Text] [Related]
19. An in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce BF; Mundy GR; Roodman GD
Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
[TBL] [Abstract][Full Text] [Related]
20. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
